Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

被引：25

作者：

Diefenbach, Catherine S. ^{[1
]}

Connors, Joseph M. ^{[2
]}

Friedberg, Jonathan W. ^{[3
,4
]}

Leonard, John P. ^{[5
]}

Kahl, Brad S. ^{[6
]}

Little, Richard F. ^{[7
]}

Baizer, Lawrence ^{[8
]}

Evens, Andrew M. ^{[9
,10
]}

Hoppe, Richard T. ^{[11
]}

Kelly, Kara M. ^{[12
]}

Persky, Daniel O. ^{[13
]}

Younes, Anas ^{[14
]}

Kostakaglu, Lale ^{[15
]}

Bartlett, Nancy L. ^{[6
]}

机构：

[1] NYU, Perlmutter Canc Ctr, 240 East 38th St,19th Floor, New York, NY 10016 USA

[2] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA

[4] Univ Rochester, Med Ctr, Div Hematol Oncol, Rochester, NY 14642 USA

[5] Weil Cornell Univ, Dept Med, New York, NY USA

[6] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA

[7] Tufts Univ, Sch Med, Div Canc Treatment & Diag, Boston, MA 02111 USA

[8] Tufts Univ, Sch Med, Coordinating Ctr Clin Trials, Boston, MA 02111 USA

[9] Tufts Univ, Sch Med, Tufts Canc Ctr, Boston, MA 02111 USA

[10] Tufts Univ, Sch Med, Div Hematol Oncol, Boston, MA 02111 USA

[11] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA

[12] Columbia Univ, Div Pediat Hematol Oncol Stem Cell Transplant, Med Ctr, New York, NY USA

[13] Univ Arizona, Ctr Canc, Dept Med, Tucson, AZ USA

[14] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[15] Mt Sinai Hosp, Dept Radiol, New York, NY 10029 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2017年 / 109卷 / 04期

基金：

美国国家卫生研究院;

关键词：

REED-STERNBERG CELLS; EPSTEIN-BARR-VIRUS; INTERNATIONAL PROGNOSTIC SCORE; INVOLVED-FIELD RADIOTHERAPY; TUMOR-ASSOCIATED MACROPHAGES; COOPERATIVE-ONCOLOGY-GROUP; RADIATION-THERAPY; BRENTUXIMAB VEDOTIN; PHASE-II; DEFINED SUBGROUPS;

D O I：

10.1093/jnci/djw249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

引用

页数：12

共 98 条

[1] Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma [J].

Adams, Hugo J. A. ;

de Klerk, John M. H. ;

Fijnheer, Rob ;

Heggelman, Ben G. F. ;

Dubois, Stefan V. ;

Nievelstein, Rutger A. J. ;

Kwee, Thomas C. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (06) :532-539

[2] Late cardiotoxicity after treatment for Hodgkin lymphoma [J].

Aleman, Berthe M. P. ;

van den Belt-Dusebout, Alexandra W. ;

De Bruin, Marie L. ;

van 't Veer, Mars B. ;

Baaijens, Margreet H. A. ;

de Boers, Jan Paul ;

Hart, Augustinus A. M. ;

Klokman, Willem J. ;

Kuenen, Marianne A. ;

Ouwens, Gabey M. ;

Bartelink, Harry ;

van Leeuwen, Flora E. .

BLOOD, 2007, 109 (05) :1878-1886

[3] Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].

Aleman, BMP ;

Raemaekers, JMM ;

Tirelli, U ;

Bortolus, R ;

van't Veer, MB ;

Lybeert, MLM ;

Keuning, JJ ;

Carde, P ;

Girinsky, T ;

van der Maazen, RWM ;

Tomsic, R ;

Vovk, M ;

van Hoof, A ;

Demeestere, G ;

Lugtenburg, PJ ;

Thomas, J ;

Schroyens, W ;

De Boeck, K ;

Baars, JW ;

Kluin-Nelemans, JC ;

Carrie, C ;

Aoudjhane, M ;

Bron, D ;

Eghbali, H ;

Smit, WGJM ;

Meerwaldt, JH ;

Hagenbeek, A ;

Pinna, A ;

Henry-Amar, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406

[4]

[Anonymous], BLOOD

[5]

[Anonymous], M AM SOC CLIN ONC JU

[6]

Ansell S, 2015, 57 M AM SOC HEM DEC

[7] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[8]

Armand P, 2015, 57 M AM SOC HEM DEC

[9] Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease [J].

Axdorph, U ;

Sjöberg, J ;

Grimfors, G ;

Landgren, O ;

Porwit-MacDonald, A ;

Björkholm, M .

ANNALS OF ONCOLOGY, 2000, 11 (11) :1405-1411

[10] Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases [J].

Bazzeh, Faiha ;

Rihani, Rawad ;

Howard, Scott ;

Sultan, Iyad .

LEUKEMIA & LYMPHOMA, 2010, 51 (12) :2198-2207

← 1 2 3 4 5 6 7 8 9 10 →